Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages) View the PDF document
Table of Contents
View the documentExecutive summary
View the documentI. Introduction
Open this folder and view contentsII. Background on the research project
Open this folder and view contentsIII. Second workshop
Close this folderIV. Preliminary findings
Open this folder and view contents1. The methods: What has been learnt?
Open this folder and view contents2. National drug policies: what has been learnt?
Open this folder and view contents3. Cross national analysis: What can be learnt at this stage?
View the document4. Broader capacity building
Open this folder and view contentsV. Conclusions of the workshop and follow-up plans
Open this folder and view contentsAnnex 1: Research proposal
View the documentAnnex 2: List of participants
View the documentAnnex 3: Agenda
View the documentAnnex 4: Questionnaire on NDP performance assessment
Open this folder and view contentsAnnex 5: Achievements of the national drug policies in the 12 countries
View the documentAnnex 6: Consolidated tables
View the documentOther documents in the DAP Research Series
 

4. Broader capacity building

The research has also allowed an important process of capacity building. Although this process has not yet been quantified, all the country teams agreed that the research had a number of outputs:

(a) Pharmaceutical sector benefits

The results of the research have increased knowledge on key aspects of NDP and on successful strategies/policies. This provides an impetus for countries and for international agencies to reconsider their own policies in the pharmaceutical sector. In addition, the research will be useful in better targeting future research in the field of national drug policies, as it will assist in identifying the main issues which need to be addressed.

(b) Benefits for future research

Conducting the research strengthened skills and research capacity not only of the principal investigators but of a large number of people at national level who were involved in collection and analysis of data. It also enhanced the ability of the researchers to utilize better existing research as the project was an exercise where all the participants learnt and benefitted from research conducted in other countries. This experienced group of people should play a critical role in the future in their own countries.

(c) Political benefits

The research improved the information base at national and global level and provided evidence to influence policy-makers (Bulgaria, the Philippines) or to delay some decisions (Sri Lanka). At the same time, it revealed the lack of monitoring and the need to get good data for policy-making.

(d) Practical tools for policy analysis

The research project also demonstrated that the two research tools, the indicators and the political mapping, could be applied in diverse national contexts, for relatively low financial expenditures, and could generate useful information for policy-makers. The project indicated that these tools deserved broader adoption by policy-makers concerned with national drug policy.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014